LILLY (ELI) & COMPANY - Form 8-K

                      SECURITIES AND EXCHANGE COMMISSION

                            Washington, D.C. 20549

                               ________________

                                   FORM 8-K

                                Current Report

                    Pursuant to Section 13 or 15(d) of the

                        Securities Exchange Act of 1934

                               ________________

        Date of Report (Date of earliest event reported): July 8, 2013

                             ELI LILLY AND COMPANY

            (Exact name of registrant as specified in its charter)

          Indiana                  001-06351                35-0470950

(State or Other Jurisdiction      (Commission            (I.R.S. Employer
     of Incorporation)           File Number)          Identification No.)
   Lilly Corporate Center                                     46285
   Indianapolis, Indiana                                    (Zip Code)
   (Address of Principal
     Executive Offices)

      Registrant's telephone number, including area code: [phone]

                      No Change

         (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On July 8, 2013, John Lechleiter, Ph.D., resumed his position as the
Company's chairman, president, and chief executive officer. As previously
announced, Dr. Lechleiter had taken a medical leave of absence beginning on May
6, 2013. Derica W. Rice, who served as acting chief executive officer during
Dr. Lechleiter's absence, will resume his position as executive vice president,
Global Services and chief financial officer. Ellen R. Marram, who served as
interim chairperson of the Board of Directors, will resume her position as the
board's lead independent director. A copy of the press release issued by the
Company on July 8, 2013 is furnished as Exhibit 99.1.

(c) The information required under this Item is provided in paragraph 5.02(b)
above and in the Company's definitive proxy statement for the 2013 annual
meeting of stockholders filed with the SEC on March 25, 2013 and is herein
incorporated by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibit 99.1 Press release issued by Eli Lilly and Company on July 8, 2013.

Exhibit No. Description of Document

99.1 Press Release dated July 8, 2013

                                  SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

ELI LILLY AND COMPANY

(Registrant)

By: _______________________________

Name: Jamie E. Haney

Title: Assistant Secretary and Counsel

Dated: July 8, 2013

                                 EXHIBIT INDEX

Exhibit No.                               Description of Document
99.1                                      Press Release dated July 8, 2013

Copyright ly 8 PR Newswire